164 related articles for article (PubMed ID: 14998848)
1. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.
Ali SM; Demers LM; Leitzel K; Harvey HA; Clemens D; Mallinak N; Engle L; Chinchilli V; Costa L; Brady C; Seaman J; Lipton A
Ann Oncol; 2004 Mar; 15(3):455-9. PubMed ID: 14998848
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.
Tamiya M; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Yasue T; Matsuura Y; Hirashima T; Kawase I
Med Oncol; 2012 Mar; 29(1):215-8. PubMed ID: 21258879
[TBL] [Abstract][Full Text] [Related]
4. [Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis--comparison with bone scintigraphy and other metabolic bone markers].
Yamamoto I; Morita R; Konishi J; Shigeno C; Ikekubo K; Hino M; Sone T; Fujimoto R
Kaku Igaku; 1995 May; 32(5):501-10. PubMed ID: 7596071
[TBL] [Abstract][Full Text] [Related]
5. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
6. Serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with metastatic breast cancer.
Maemura M; Iino Y; Yokoe T; Takei H; Horiguchi J; Koibuchi Y; Ikeda F; Ohwada S; Takeyoshi I; Morishita Y
Oncol Rep; 2000; 7(6):1333-8. PubMed ID: 11032939
[TBL] [Abstract][Full Text] [Related]
7. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
[TBL] [Abstract][Full Text] [Related]
9. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
11. Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors.
Jablonka F; Schindler F; Lajolo PP; Pinczowski H; Fonseca FL; Barbieri A; Massonetto LH; Katto FT; Del Giglio A
Sao Paulo Med J; 2009 Jan; 127(1):19-22. PubMed ID: 19466290
[TBL] [Abstract][Full Text] [Related]
12. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
13. Markers of bone metastases in breast and lung cancers.
Bilgin E; Yasasever V; Soydinc HO; Yasasever CT; Ozturk N; Duranyildiz D
Asian Pac J Cancer Prev; 2012; 13(9):4331-4. PubMed ID: 23167338
[TBL] [Abstract][Full Text] [Related]
14. Serum Levels of NTx and TRACP5b in Giant Cell Tumor of Bone and its Clinical Implications.
Chen J; Younusi A; Cao L; Xu L; Zhou Y; Zhen T; Song X
Clin Lab; 2015; 61(8):1077-81. PubMed ID: 26427154
[TBL] [Abstract][Full Text] [Related]
15. Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
Shizuku M; Shibata M; Okumura M; Takeuchi D; Kikumori T; Mizuno Y
Breast Cancer; 2020 Nov; 27(6):1065-1071. PubMed ID: 32415556
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients.
Maeno Y; Inaba M; Okuno S; Yamakawa T; Ishimura E; Nishizawa Y
Clin Chem; 2005 Dec; 51(12):2312-7. PubMed ID: 16223890
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
